LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.11 -0.89

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.1

Máximo

1.12

Métricas clave
By Trading Economics
Ingresos	17M -26M
Empleados	171
EBITDA	19M -23M

Dividendos
By Dow Jones
Próximas Ganancias	26 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-31M 72M
Apertura anterior	2
Cierre anterior	1.11

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 feb 2026, 23:21 UTC

Adquisiciones, fusiones, absorciones

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 feb 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 feb 2026, 23:40 UTC

Charlas de Mercado

Gold Falls on Possible Position Adjustments -- Market Talk

15 feb 2026, 23:06 UTC

Ganancias

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 feb 2026, 23:04 UTC

Ganancias

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 feb 2026, 23:04 UTC

Ganancias

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Ganancias

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Ganancias

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 feb 2026, 22:58 UTC

Ganancias

Warner Bros. Lands Ninth Straight Box Office Winner With 'Wuthering Heights' -- Barrons.com

15 feb 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 feb 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 feb 2026, 22:52 UTC

Adquisiciones, fusiones, absorciones

Qube Shareholders to Receive A$5.20/Share in Cash

15 feb 2026, 22:52 UTC

Adquisiciones, fusiones, absorciones

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 feb 2026, 21:35 UTC

Ganancias

Warner Bros. Lands Ninth Straight Box Office Winner With 'Wuthering Heights' -- Barrons.com

15 feb 2026, 19:19 UTC

Adquisiciones, fusiones, absorciones

An S&P Global International Insider Bought Up Stock -- Barrons.com

14 feb 2026, 22:02 UTC

Ganancias

Looking for Dividends? Consider Europe. -- Barrons.com

14 feb 2026, 09:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 feb 2026, 21:57 UTC

Ganancias

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 feb 2026, 21:20 UTC

Ganancias

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13 feb 2026, 21:05 UTC

Adquisiciones, fusiones, absorciones

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13 feb 2026, 20:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 feb 2026, 20:45 UTC

Charlas de Mercado

Dollar Pares Down Early Losses -- Market Talk

13 feb 2026, 20:39 UTC

Charlas de Mercado

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13 feb 2026, 20:28 UTC

Charlas de Mercado

Oil Settles Week Lower -- Market Talk

13 feb 2026, 19:51 UTC

Ganancias

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13 feb 2026, 19:32 UTC

Charlas de Mercado

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:32 UTC

Charlas de Mercado

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13 feb 2026, 19:29 UTC

Ganancias

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13 feb 2026, 18:18 UTC

Adquisiciones, fusiones, absorciones

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc Esperado

Consenso

By TipRanks

Vender

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.